SEC Form 4 · accession 0000950103-18-008190
Translate Bio, Inc. · TBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 2, 2018
Accepted (ET)
Jul 2, 2018 · 9:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001693415
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 2, 2018 | J | 183,619 | $0.00 | A | 7,078,945 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were issued upon the closing of the Issuer's initial public offering in satisfaction of contractual obligations, based on the initial public offering price of $13.00 per share, without payment of any additional consideration by Shire Human Genetic Therapies, Inc. at the time of issuance.
- F2These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Shire plc. Shire plc is an indirect beneficial owner of the reported securities.